Meta-analysis on the efficacy and safety of Fluoxetine in the treatment of post-stroke depression
WAND Dou1,2 LI Tao1,2 YANG Yifan1 MAO Meiling1 YAN Yongmei1,2
1.The First Clinical Medical College of Shaanxi University of Traditional Chinese Medicine, Shaanxi Province, Xianyang 712046, China;
2.Department of Encephalopathy, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Shaanxi Province, Xianyang 712000, China
Abstract：Objective To systematically evaluate the efficacy and safety of Fluoxetine in the treatment of post-stroke depression (PSD). Methods Literatures related to Fluoxetine in the treatment of PSD from PubMed, The Cochrane Library, CBM, CNKI, Wanfang Data and VIP were searched by computer. The retrieval time limit is from inception to September 2020. The literatures were selected according to the inclusion and exclusion criterias, the data was extracted and the literature quality was evaluated. RevMan 5.3 software was used for meta-analysis. Results A total of 763 patients were included in nine clinical randomized controlled studies. Meta-analysis results showed that the score of Hamilton depression scale in the Fluoxetine group was lower than that in the control group (SMD = -4.11, 95%CI [-5.31, -2.91], P ＜ 0.000 01). The score of national institute of health stroke scale in the Fluoxetine group was lower than that in the control group (SMD = -1.50, 95%CI [-2.41, -0.59], P = 0.001). There was no significant difference in the incidence of adverse reactions between Fluoxetine group and control group (RR = 2.11, 95%CI [0.05, 92.23], P = 0.70). Conclusion Fluoxetine can improve the depressive symptoms and neurological deficits in PSD patients without increasing the adverse reactions. However, whether this drug can be widely used in clinic still needs to carry out more high-quality studies to further prove the clinical efficacy.
王豆1,2 李涛1,2 杨一帆1 毛美玲1 闫咏梅1,2. 氟西汀治疗卒中后抑郁有效性和安全性的meta分析[J]. 中国医药导报, 2021, 18(16): 74-77.
WAND Dou1,2 LI Tao1,2 YANG Yifan1 MAO Meiling1 YAN Yongmei1,2. Meta-analysis on the efficacy and safety of Fluoxetine in the treatment of post-stroke depression. 中国医药导报, 2021, 18(16): 74-77.
[1] 王少石，周新雨，朱春燕.卒中后抑郁临床实践的中国专家共识[J].中国卒中杂志，2016，11（8）：685-693.
[2] Hackett ML，Pickles K. PartⅠ：frequency of depression after stroke：an updated systematic review and meta-analysis of observational studies [J]. Int J Stroke，2014，9（8）：1017-1025.
[3] 范小荷，杨卫边，孙丹.卒中后抑郁的发病率及其社会心理因素的研究进展[J].临床医药文献电子杂志，2017，4（77）：15244.
[4] 曾天闻.盐酸氟西汀治疗脑卒中后抑郁的临床效果观察[J].中国医药指南，2019，17（36）：143.
[5] 岳霞，王灵芝，杨小敏，等.脑梗死后抑郁症患者应用氟西汀干预治疗的有效性分析[J].中国社区医师，2020，36（29）：82-83.
[6] 王政林，邓海霞，胡嗣钦，等.氟西汀对卒中后抑郁的预防效果及神经功能康复的促进作用观察[J].基因组学与应用生物学，2018，37（11）：4961-4967.
[7] 蔡长江.氟西汀治疗脑卒中后抑郁症的临床疗效及对血浆皮质醇的影响[J].海峡药学，2010，22（5）：238-240.
[8] 畅慧君，张其相，赵建民.氟西汀治疗卒中后抑郁患者的临床观察[J].中国伤残医学，2010，18（4）：57-58.
[9] 陈德鹏.氟西汀改善脑卒中后抑郁及神经功能缺损患者的临床研究[J].中国当代医药，2016，23（22）：61-63.
[10] 林泽怀.氟西汀改善脑卒中后抑郁及神经功能缺损的临床研究[J].泰山医学院学报，2016，37（11）：1260-1261.
[11] 马菊香.脑卒中后合并抑郁的临床观察[J].吉林医学，2011，32（12）：383.
[12] 孙建田.氟西汀治疗急性首发脑卒中后抑郁的临床对照研究[J].安徽医学，2009，30（4）：440-442.
[13] 孙燕霞，李淑萍.氟西汀改善脑卒中后抑郁及神经功能缺损患者的临床分析[J].齐齐哈尔医学院学报，2014， 35（10）：1531-1532.
[14] 王雅斌，伍琳，林悦静.氟西汀治疗脑卒中后抑郁症临床分析[J].中国当代医药，2012，19（15）：41-42.
[15] 朱风文.脑卒中后抑郁对神经功能康复影响的临床观察[J].内蒙古中医药，2013，32（23）：83-84.
[16] Corallo F，Scarfì C，Arcadi FA，et al. Role of functional pharmacological therapy in post-stroke depression：a narrative review [J]. J Int Med Res，2020，48（10）：1-11.
[17] 陈顺，庞涛.脑卒中后抑郁的研究进展[J].中国医药导报，2019，16（8）：30-34.
[18] Lundstrm E，Isaksson E，Nsman P，et al. Safety and efficacy of fluoxetine on functional outcome after acute stroke （AFFINITY）：a randomised，double-blind，placebo-controlled trial [J]. Lancet Neurol，2020，19（8）：651-660.
[19] Millard SJ，Lum JS，Fernandez F，et al. The effects of perinatal fluoxetine exposure on emotionality behaviors and cortical and hippocampal glutamatergic receptors in female Sprague-Dawley and Wistar-Kyoto rats [J]. Prog Neuropsychopharmacol Biol Psychiatry，2021，108：110174.
[20] 刘增雪，陆静珏，周一心.关于卒中后抑郁发病机制的研究新进展[J].中国医药导报，2019，16（2）：24-28.
[21] Legg LA，Tilney R，Hsieh CF，et al. Selective serotonin reuptake inhibitors （SSRIs） for stroke recovery [J]. Cochrane Database Syst Rev，2019，2019（11）：CD009286.
[22] D’Anci KE，Uhl S，Oristaglio J，et al. Treatments for Poststroke Motor Deficits and Mood Disorders：A Systematic Review for the 2019 U. S. Department of Veterans Affairs and U. S. Department of Defense Guidelines for Stroke Rehabilitation [J]. Ann Intern Med，2019，171（12）：906-915.
[23] Lee JY，Lee HE，Kang SR，et al. Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood-brain barrier disruption [J]. Neuropharmacology，2014，79：161-171.
[24] Zahrai A，Vahid-Ansari F，Daigle M，et al. Fluoxetine-induced recovery of serotonin and norepinephrine projections in a mouse model of post-stroke depression [J]. Transl Psychiatry，2020，10（1）：334.
[25] 李爱平，田静，周芝文，等.氟西汀对卒中后抑郁模型大鼠的行为及海马神经元新生的影响[J].中国比较医学杂志，2018，28（12）：41-47.
[26] 方玲，马婉.氟西汀对脑卒中后抑郁大鼠学习记忆能力和氧化应激反应的影响[J].中国老年学杂志，2018，38（22）：5545-5547.
[27] Gu SC，Wang CD. Early Selective Serotonin Reuptake Inhibitors for Recovery after Stroke：A Meta-Analysis and Trial Sequential Analysis [J]. J Stroke Cerebrovasc Dis，2018，27（5）：1178-1189.
京公网安备 11010502046598号